Anne-Sophie Wattiez

Anne-Sophie Wattiez

Auto-generated profile, based on publicly available information

Anne-Sophie Wattiez

Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA, United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2020 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
AWAnne-Sophie Wattiez
Anne-Sophie Wattiez
LSLevi P. Sowers
Levi P. Sowers
ARAndrew F. Russo
Andrew F. Russo
Introduction: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a critical player in migraine pathophysiology. Excitement has grown regarding CGRP because of the development and clinical testing of drugs targeting CGRP or its receptor. While these drugs alleviate migraine symptoms in half of patients, the remaining unresponsive half of this population creates an impetus to address unanswered questions that exist in this field. Areas covered: We describe the role of CGRP in migraine pathophysiology and CGRP-targeted therapeutics currently under development and in use. We also discuss how a second CGRP receptor may provide a new therapeutic target. Expert opinion: CGRP targeting drugs have shown a remarkable safety profile. We speculate that this may reflect the redundancy of peptides within the CGRP family and a second CGRP receptor that may compensate for reduced CGRP activity. Furthermore, we propose that an inherent safety feature of peptide-blocking antibodies is attributed to the fundamental nature of peptide release, which occurs as a large bolus in short bursts of volume transmission. These facts support the development of more refined CGRP therapeutic drugs, as well as drugs that target other neuropeptides. We believe that the future of migraine research is bright with exciting advances on the horizon.

31 January 2019 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
DVDoga Vuralli
Doga Vuralli
AWAnne-Sophie Wattiez
Anne-Sophie Wattiez
ARAndrew F. Russo
Andrew F. Russo
HBHayrunnisa Bolay
Hayrunnisa Bolay
Animal models have provided a growing body of information about the pathophysiology of headaches and novel therapeutic targets. In recent years, experiments in awake animals have gained attention as more relevant headache models. Pain can be assessed in animals using behavioral alterations, which includes sensory-discriminative, affective-emotional and cognitive aspects. Spontaneous behavioral alterations such as increased grooming, freezing, eye blinking, wet dog shake and head shake and decreased locomotion, rearing, food or water consumption observed during pain episodes are oftentimes easy to translate into clinical outcomes, but are giving little information about the localization and modality of the pain. Evoked pain response such as tactile and thermal hypersensitivity measures are less translatable but gives more insight into mechanisms of action. Mechanical allodynia is usually assessed with von Frey monofilaments and dynamic aesthesiometer, and thermal allodynia can be evaluated with acetone evaporation test and Hargreaves’ test in animal models. Anxiety and depression are the most frequent comorbid diseases in headache disorders. Anxiety-like behaviors are evaluated with the open-field, elevated plus-maze or light/dark box tests. Interpretation of the latter test is challenging in migraine models, as presence of photophobia or photosensitivity can also be measured in light/dark boxes. Depressive behavior is assessed with the forced-swim or tail suspension tests. The majority of headache patients complain of cognitive symptoms and migraine is associated with poor cognitive performance in clinic-based studies. Cluster headache and tension type headache patients also exhibit a reversible cognitive dysfunction during the headache attacks. However, only a limited number of animal studies have investigated cognitive aspects of headache disorders, which remains a relatively unexplored aspect of these pathologies. Thus, the headache field has an excellent and growing selection of model systems that are likely to yield exciting advances in the future.

9 July 2018 in Pain
Verified
Journal Article
Closed access
BRBrandon J. Rea
Brandon J. Rea
AWAnne-Sophie Wattiez
Anne-Sophie Wattiez
JWJayme S. Waite
Jayme S. Waite
WCWilliam C. Castonguay
William C. Castonguay
CSChantel M. Schmidt
Chantel M. Schmidt
ARAndrew F. Russo
Andrew F. Russo
Migraine is the third most common disease in the world (behind dental caries and tension-type headache) with an estimated global prevalence of 15%, yet its etiology remains poorly understood. Recent clinical trials have heralded the potential of therapeutic antibodies that block the actions of the neuropeptide calcitonin gene–related peptide (CGRP) or its receptor to prevent migraine. Calcitonin gene–related peptide is believed to contribute to trigeminal nerve hypersensitivity and photosensitivity in migraine, but a direct role in pain associated with migraine has not been established. In this study, we report that peripherally administered CGRP can act in a light-independent manner to produce spontaneous pain in mice that is manifested as a facial grimace. As an objective validation of the orbital tightening action unit of the grimace response, we developed a squint assay using a video-based measurement of the eyelid fissure, which confirmed a significant squint response after CGRP injection, both in complete darkness and very bright light. These indicators of discomfort were completely blocked by preadministration of a monoclonal anti-CGRP–blocking antibody. However, the nonsteroidal anti-inflammatory drug meloxicam failed to block the effect of CGRP. Interestingly, an apparent sex-specific response to treatment was observed with the antimigraine drug sumatriptan partially blocking the CGRP response in male, but not female mice. These results demonstrate that CGRP can induce spontaneous pain, even in the absence of light, and that the squint response provides an objective biomarker for CGRP-induced pain that is translatable to humans.

1 August 2010 in Molecular Therapy
Verified
Journal Article
Open access
XPXavier Pichon
Xavier Pichon
AWAnne S Wattiez
Anne S Wattiez
CBCarine Becamel
Carine Becamel
IEIngrid Ehrlich
Ingrid Ehrlich
JBJoel Bockaert
Joel Bockaert
CCChristine Courteix
Christine Courteix
Antidepressants are one of the first-line treatments for neuropathic pain. Despite the influence of serotonin (5-hydroxytryptamine, 5-HT) in pain modulation, selective serotonin reuptake inhibitors (SSRIs) are less effective than tricyclic antidepressants. Here, we show, in diabetic neuropathic rats, an alteration of the antihyperalgesic effect induced by stimulation of 5-HT2A receptors, which are known to mediate SSRI-induced analgesia. 5-HT2A receptor density was not changed in the spinal cord of diabetic rats, whereas postsynaptic density protein-95 (PSD-95), one of the PSD-95/disc large suppressor/zonula occludens-1 (PDZ) domain containing proteins interacting with these receptors, was upregulated. Intrathecal injection of a cell-penetrating peptidyl mimetic of the 5-HT2A receptor C-terminus, which disrupts 5-HT2A receptor–PDZ protein interactions, induced an antihyperalgesic effect in diabetic rats, which results from activation of 5-HT2A receptors by endogenous 5-HT. The peptide also enhanced antihyperalgesia induced by the SSRI fluoxetine. Its effects likely resulted from an increase in receptor responsiveness, because it revealed functional 5-HT2A receptor-operated Ca2+ responses in neurons, an effect mimicked by knockdown of PSD-95. Hence, 5-HT2A receptor/PDZ protein interactions might contribute to the resistance to SSRI-induced analgesia in painful diabetic neuropathy. Disruption of these interactions might be a valuable strategy to design novel treatments for neuropathic pain and to increase the effectiveness of SSRIs.

3 March 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
AWA‐S Wattiez
A‐S Wattiez
FLF Libert
F Libert
APA‐M Privat
A‐M Privat
SLS Loiodice
S Loiodice
JFJ Fialip
J Fialip
CCChristine Courteix
Christine Courteix
BACKGROUND AND PURPOSE: Antidepressants are one of the recommended treatments for neuropathic pain. However, their analgesic action remains unpredictable, and there are no selection criteria for clinical use. Better knowledge of their mechanism of action could help highlight differences underlying their unequal efficacy.EXPERIMENTAL APPROACH: We compared the activity of a tricyclic antidepressant (clomipramine) with selective 5‐HT and noradrenaline reuptake inhibitors (milnacipran and duloxetine) in streptozocin‐induced diabetic and chronic constriction nerve injury‐induced neuropathic rats, after repeated injections. We looked for an opioidergic mechanism in their action.KEY RESULTS: Abolition of mechanical hyperalgesia was observed in mononeuropathic rats after five injections of clomipramine (5 mg·kg−1, s.c.) and milnacipran (10 or 20 mg·kg−1, i.p.) and in diabetic rats after clomipramine. An additional antinociceptive effect was obtained with five injections of duloxetine (3 mg·kg−1, i.p.) in both models and milnacipran (10 mg·kg−1, i.p.) in diabetic rats. These effects were observed with plasma antidepressant concentrations similar to those found in patients treated for neuropathic pain. Naloxone (1 mg·kg−1, i.v.) only suppressed the anti‐hyperalgesic effects of clomipramine in both models of pain and of milnacipran in the traumatic model.CONCLUSIONS AND IMPLICATIONS: The opioid system appears to be involved in the mechanism of action of antidepressants that only have an anti‐hyperalgesic effect but not in those that have a stronger (i.e. antinociceptive) effect. These differences between the antidepressants occurred whatever the aetiology of the neuropathy and, if confirmed in clinical trials, could be used to decide which antidepressant is administered to a patient with neuropathic pain.

1 January 2018
Verified
Book Chapter
Closed access
PDF file
AWAnne-Sophie Wattiez
Anne-Sophie Wattiez
MWMengya Wang
Mengya Wang
ARAndrew F. Russo
Andrew F. Russo